Showing 3691-3700 of 7372 results for "".
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se
- Galderma Names New Managers of Prescription Business and Aesthetic & Corrective Business Units; Dr. Kelly Huang to Obalonhttps://practicaldermatology.com/news/alisa-lask-to-oversee-galdermas-aesthetic-corrective-business-unit-dr-kelly-huang-to-obalon/2458064/Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask <
- Link Found Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agenthttps://practicaldermatology.com/news/link-found-between-a-molecular-driver-of-melanoma-progression-and-novel-therapeutic-agent/2458065/Research linking autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis, may guide effective use of autophagy inhibitors. The findings appear online in Cancer Research. Autophagy allows cancer cells to survive under stressful cond
- AD Breakthrough? Medimetriks' MM36 Achieves Rapid Itch Relief, Safety in Phase 2 Studyhttps://practicaldermatology.com/news/ad-breakthrough-medimetriks-mm36-achieves-rapid-itch-relief-safety-in-phase-2-study/2458068/Medimetriks’ PDE4 inhibitor, MM36, appears to be safe, well-tolerated and provides rapid itch relief when applied twice daily to pediatric and adolescent atopic dermatitis (AD) patients, according to results of a Phase 2 study. The company ex
- Skin Color Affects Skin Sensitivity to Heat and Mechanical Stimulihttps://practicaldermatology.com/news/skin-color-affects-skin-sensitivity-to-heat-and-mechanical-stimuli/2458069/Researchers at the Bluestone Center for Clinical Research at the New York University College of Dentistry (NYU Dentistry) have identified a novel molecular mechanism which explains why dark-skinned and light-skinned people respond differently to heat and mechanical stimulation. In a study
- Study: Most Melanomas Don't Arise From Existing Moleshttps://practicaldermatology.com/news/study-most-melanomas-dont-arise-from-existing-moles/2458072/Less than one-third of melanomas (29 percent) arose from an existing mole, while the vast majority (71 percent) appeared on the skin as new spots, according to research in the Journal of the American Academy of Dermatology</
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- DermTech Appoints New Member to Board of Directorshttps://practicaldermatology.com/news/dermtech-appoints-new-members-to-board-of-directors/2458080/DermTech, Inc., appointed Herman “Herm” Rosenman to its Board of Directors. Mr. Rosenman, CPA, brings more than 30 years of public company operating and financial experience to DermTech. He received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from
- The Prescription Dermatological Drugs Market Forecasthttps://practicaldermatology.com/news/the-prescription-dermatological-drugs-market-forecast/2458079/The "World Prescription Dermatological Drugs Market, 10th Edition" report, now available from Research and Markets shows the field
- Protea Expands Clinical Study for New Melanoma Testhttps://practicaldermatology.com/news/protea-expands-clinical-study-for-new-melanoma-test/2458083/Protea Biosciences Group, Inc. is expanding its clinical research study for their new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples, the company reports. The propr